<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Retrovirology</journal-id><journal-title>Retrovirology</journal-title><issn pub-type="epub">1742-4690</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1742-4690-3-11</article-id><article-id pub-id-type="pmid">16460575</article-id><article-id pub-id-type="doi">10.1186/1742-4690-3-11</article-id><article-categories><subj-group subj-group-type="heading"><subject>Short Report</subject></subj-group></article-categories><title-group><article-title>Patterns of evolution of host proteins involved in retroviral pathogenesis</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Ortiz</surname><given-names>Millan</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>millan.Ortiz-serrano@chuv.ch</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Bleiber</surname><given-names>Gabriela</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Gabriela.x.bleiber@gsk.com</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Martinez</surname><given-names>Raquel</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Raquel.martinez@chuv.ch</email></contrib><contrib id="A4" corresp="yes" contrib-type="author"><name><surname>Kaessmann</surname><given-names>Henrik</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>Henrik.Kaessmann@unil.ch</email></contrib><contrib id="A5" corresp="yes" contrib-type="author"><name><surname>Telenti</surname><given-names>Amalio</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>amalio.telenti@chuv.ch</email></contrib></contrib-group><aff id="I1"><label>1</label>Institute of Microbiology and University Hospital, University of Lausanne, Switzerland</aff><aff id="I2"><label>2</label>Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland</aff><pub-date pub-type="collection"><year>2006</year></pub-date><pub-date pub-type="epub"><day>7</day><month>2</month><year>2006</year></pub-date><volume>3</volume><fpage>11</fpage><lpage>11</lpage><ext-link ext-link-type="uri" xlink:href="http://www.retrovirology.com/content/3/1/11"/><history><date date-type="received"><day>23</day><month>12</month><year>2005</year></date><date date-type="accepted"><day>7</day><month>2</month><year>2006</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2006 Ortiz et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2006</copyright-year><copyright-holder>Ortiz et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Ortiz Millan millan.Ortiz-serrano@chuv.ch </dc:author><dc:title> Patterns of evolution of host proteins involved in retroviral pathogenesis </dc:title><dc:date>2006</dc:date><dcterms:bibliographicCitation>Retrovirology 3(1): 11-. (2006)</dcterms:bibliographicCitation><dc:identifier type="sici">1742-4690(2006)3:1&#x0003c;11&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1742-4690</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Evolutionary analysis may serve as a useful approach to identify and characterize host defense and viral proteins involved in genetic conflicts. We analyzed patterns of coding sequence evolution of genes with known (<italic>TRIM5</italic>&#x003b1; and <italic>APOBEC3G</italic>) or suspected (<italic>TRIM19</italic>/<italic>PML</italic>) roles in virus restriction, or in viral pathogenesis (<italic>PPIA</italic>, encoding Cyclophilin A), in the same set of human and non-human primate species.</p></sec><sec><title>Results and conclusion</title><p>This analysis revealed previously unidentified clusters of positively selected sites in <italic>APOBEC3G </italic>and <italic>TRIM5</italic>&#x003b1; that may delineate new virus-interaction domains. In contrast, our evolutionary analyses suggest that <italic>PPIA </italic>is not under diversifying selection in primates, consistent with the interaction of Cyclophilin A being limited to the HIV-1M/SIVcpz lineage. The strong sequence conservation of the <italic>TRIM19/PML </italic>sequences among primates suggests that this gene does not play a role in antiretroviral defense.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Evolutionary genomics approaches have been proposed as powerful tools to identify protein regions relevant for host-pathogen interactions [<xref ref-type="bibr" rid="B1">1</xref>]. Identifying signatures of genetic conflict can open the way to biological testing of hypotheses regarding the function of host proteins. In retrovirology, the utility of this approach was recently demonstrated in evolutionary analyses of the antiretroviral defense genes <italic>TRIM5</italic>&#x003b1;, encoding a retrovirus restriction factor targeting the viral capsid [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>], and <italic>APOBEC3G</italic>, coding for a cytidine deaminase that hypermutates viral DNA in primates [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B6">6</xref>]. Both genes were shown to have been shaped by positive selection, which led to the rapid fixation of adaptive amino acid replacement substitutions. The two genes revealed two different patterns of positive selection: a localized region of rapid change in <italic>TRIM5</italic>&#x003b1; [<xref ref-type="bibr" rid="B3">3</xref>], and a pattern where positively selected residues are scattered throughout the sequence in <italic>APOBEC3G </italic>[<xref ref-type="bibr" rid="B5">5</xref>].</p><p>To assess the potential of an evolutionary approach to identify further primate genes/proteins involved in virus defense, we analyzed coding sequence evolution of two additional genes, <italic>TRIM19 </italic>(<italic>PML</italic>) and <italic>PPIA</italic>, and reassessed the selective signatures of <italic>TRIM5</italic>&#x003b1; and <italic>APOBEC3G </italic>in a common set of primates, representing 40 million years of evolution [<xref ref-type="bibr" rid="B7">7</xref>]. TRIM19 (PML) was proposed to possess anti(retro)viral activity [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>], while Cyclophilin A, encoded by <italic>PPIA </italic>(peptidyl-prolyl cis-trans isomerase), is incorporated into HIV-1 particles through an interaction with the viral capsid [<xref ref-type="bibr" rid="B10">10</xref>]. Cyclophilin A is incorporated only into viral particles of viruses of the HIV-1M/SIV<sub>CPZ </sub>lineage, where it is required for viral replication [<xref ref-type="bibr" rid="B11">11</xref>].</p><p>To trace the evolutionary history of these genes, we first sequenced their coding regions from eleven primate species [see Additional files <xref ref-type="supplementary-material" rid="S1">1</xref> and <xref ref-type="supplementary-material" rid="S2">2</xref>]. We then analyzed their substitutional patterns in the framework of the accepted primate phylogeny [<xref ref-type="bibr" rid="B7">7</xref>] using several codon-based maximum likelihood procedures as implemented in the codeml tool of the PAML program package [<xref ref-type="bibr" rid="B12">12</xref>] (Figure <xref ref-type="fig" rid="F1">1</xref>).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Phylogenetic trees of candidate antiviral defense genes</bold>. <italic>K</italic><sub><italic>A</italic></sub>/<italic>K</italic><sub><italic>S </italic></sub>values and the estimated number of nonsynonymous and synonymous substitutions (in parentheses) for each branch are indicated. Approximate divergence times in millions of years (mya) are shown [7].</p></caption><graphic xlink:href="1742-4690-3-11-1"/></fig><p>To obtain an overview of the coding sequence evolution, we estimated the number of nonsynonymous (<italic>K</italic><sub>A</sub>) over synonymous (<italic>K</italic><sub>S</sub>) substitutions per site (averaged over the entire sequence) for each branch of the trees using the free-ratio model of codeml [<xref ref-type="bibr" rid="B12">12</xref>]. Similarly to previous reports [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>], this analysis revealed generally high <italic>K</italic><sub>A</sub>/<italic>K</italic><sub>S </sub>values on the different branches of the <italic>TRIM5</italic>&#x003b1; and <italic>APOBEC3G </italic>trees (average <italic>K</italic><sub>A</sub>/<italic>K</italic><sub>S </sub>~1.1 for both genes), indicating that these genes show accelerated amino acid replacement rates due to the action of positive selection [<xref ref-type="bibr" rid="B13">13</xref>]. In contrast, <italic>PPIA </italic>and <italic>TRIM19 </italic>(PML) show low <italic>K</italic><sub>A</sub>/<italic>K</italic><sub>S </sub>values (0.05 and 0.15, respectively, when averaged over the entire tree), suggesting that their protein sequences have been strongly preserved by purifying selection (Figure <xref ref-type="fig" rid="F1">1</xref>).</p><p>In more detailed analyses, we then utilized models that allow for different <italic>K</italic><sub>A</sub>/<italic>K</italic><sub>S </sub>rates at different sites of the sequences, because adaptive evolution often occurs at a limited number of sites [<xref ref-type="bibr" rid="B14">14</xref>]. We first compared a null model ("M1a", [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>]), which assumes two site classes (sites under purifying selection and neutrally evolving sites), to an alternative model ("M2a", [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>]), which adds a third site class that allows for sites with <italic>K</italic><sub>A</sub>/<italic>K</italic><sub>S </sub>&#x0003e; 1, using likelihood ratio tests [<xref ref-type="bibr" rid="B17">17</xref>]. This comparison revealed that the alternative model provides a significantly better fit (<italic>P </italic>&#x0003c; 10<sup>-30</sup>) for the <italic>TRIM5</italic>&#x003b1; and <italic>APOBEC3G </italic>genes than the null model, whereas the null model could not be rejected for <italic>TRIM19 </italic>and <italic>PPIA </italic>(Table <xref ref-type="table" rid="T1">1</xref>). The <italic>K</italic><sub>A</sub>/<italic>K</italic><sub>S </sub>for the additional site class is larger than 1 for both <italic>TRIM5</italic>&#x003b1; (<italic>K</italic><sub>A</sub>/<italic>K</italic><sub>S </sub>~6.4) and <italic>APOBEC3G </italic>(<italic>K</italic><sub>A</sub>/<italic>K</italic><sub>S </sub>~4.4), strongly suggesting adaptive protein evolution driven by positive selection at a subset of sites. Thus, this analysis supports the hypothesis that <italic>TRIM5</italic>&#x003b1; and <italic>APOBEC3G </italic>evolved under positive selection. Contrary to this, nearly all sites of <italic>TRIM19 </italic>and <italic>PPIA </italic>(91.5% and 100%, respectively) are under purifying selection (Table <xref ref-type="table" rid="T1">1</xref>).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Codeml analyses using site-specific models.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center" colspan="6"><bold><italic>TRIM5</italic>&#x003b1;</bold></td></tr></thead><tbody><tr><td align="center">Site-specific Models<sup>a</sup></td><td align="left">&#x003c9;<sub>0</sub><sup>b</sup></td><td align="left">&#x003c9;<sub>1</sub><sup>c</sup></td><td align="left">&#x003c9;<sub>2</sub><sup>d</sup></td><td align="left">LogL</td><td align="left">Sites with &#x003c9; &#x0003e; 1 <sup>e</sup></td></tr><tr><td align="center">C: M1a</td><td align="left">0.00 (34.91%)</td><td align="left">1.00 (65.09%)</td><td></td><td align="left">-4117.12</td><td></td></tr><tr><td align="center">D: M2a</td><td align="left">0.00 (26.04%)</td><td align="left">1.00 (61.67%)</td><td align="left">6.37* (12.29%)</td><td align="left">-4087.97</td><td align="left">11 sites</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="center" colspan="6"><bold><italic>APOBEC3G</italic></bold></td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="center">Site-specific Models</td><td align="left">&#x003c9;<sub>0</sub></td><td align="left">&#x003c9;<sub>1</sub></td><td align="left">&#x003c9;<sub>2</sub></td><td align="left">LogL</td><td align="left">Sites with &#x003c9; &#x0003e; 1</td></tr><tr><td align="center">C: M1a</td><td align="left">0.03 (37.56%)</td><td align="left">1.00 (62.44%)</td><td></td><td align="left">-4187.55</td><td></td></tr><tr><td align="center">D: M2a</td><td align="left">0.00 (28.28%)</td><td align="left">1.00 (48.60%)</td><td align="left">4.40* (23.11%)</td><td align="left">-4148.85</td><td align="left">24 sites</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="center" colspan="6"><bold><italic>TRIM19 (PML)</italic></bold></td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="center">Site-specific Models</td><td align="left">&#x003c9;<sub>0</sub></td><td align="left">&#x003c9;<sub>1</sub></td><td align="left">&#x003c9;<sub>2</sub></td><td align="left">LogL</td><td align="left">Sites with &#x003c9; &#x0003e; 1</td></tr><tr><td align="center">C: M1a</td><td align="left">0.09 (91.47%)</td><td align="left">1.00 (8.53%)</td><td></td><td align="left">-5215.40</td><td></td></tr><tr><td align="center">D: M2a</td><td align="left">0.11 (97.25%)</td><td align="left">1.00 (0.00%)</td><td align="left">2.5 (2.75%)</td><td align="left">-5214.46</td><td align="left">n/a <sup>f</sup></td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="center" colspan="6"><bold><italic>PPIA (Cyclophilin A)</italic></bold></td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="center">Site-specific Models</td><td align="left">&#x003c9;<sub>0</sub></td><td align="left">&#x003c9;<sub>1</sub></td><td align="left">&#x003c9;<sub>2</sub></td><td align="left">LogL</td><td align="left">Sites with &#x003c9; &#x0003e; 1</td></tr><tr><td align="center">C: M1a</td><td align="left">0.05 (100%)</td><td align="left">1.00 (0%)</td><td></td><td align="left">-751.04</td><td></td></tr><tr><td align="center">D: M2a</td><td align="left">0.05 (100%)</td><td align="left">1.00 (0.00%)</td><td align="left">1.00 (0.00%)</td><td align="left">-751.04</td><td align="left">n/a <sup>f</sup></td></tr></tbody></table><table-wrap-foot><p><sup>a </sup>the likelihood models used are described in the text</p><p><sup>b </sup>class of sites under purifying selection</p><p><sup>c </sup>class of sites evolving neutrally</p><p><sup>d </sup>class of sites that may show <italic>K</italic><sub>A</sub>/<italic>K</italic><sub>S </sub>&#x0003e; 1</p><p><sup>e </sup>sites pinpointed to be under positive selection by Bayes Empirical Bayes analysis</p><p><sup>f </sup>test not applicable (M1a and M2a not significantly different)</p></table-wrap-foot></table-wrap><p>Using a recently developed Bayesian approach [<xref ref-type="bibr" rid="B16">16</xref>], we analyzed the site class under positive selection in <italic>TRIM5</italic>&#x003b1; and <italic>APOBEC3G </italic>in more detail. For <italic>TRIM5</italic>&#x003b1;, 11 of 493 (2%) codon sites can be predicted to be positively selected with high confidence (<italic>P </italic>&#x0003e; 0.95, Figure <xref ref-type="fig" rid="F2">2A</xref>). Two clusters of positive selection are found in the SPRY domain. The first cluster resides between amino acids 322 to 340 in the variable region 1 (v1, [<xref ref-type="bibr" rid="B18">18</xref>]), a region previously described as a "patch" of positive selection [<xref ref-type="bibr" rid="B3">3</xref>]. Replacement of the v1 region, or of specific amino acids within v1, modifies the restriction pattern of TRIM5&#x003b1; [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>]. The second cluster, localized between amino acids 381 to 389, corresponds to the previously described variable region v2 of the SPRY domain [<xref ref-type="bibr" rid="B18">18</xref>]. Substitution of the human v2 region by a Rhesus monkey v2 exhibits no inhibitory activity against HIV-1 or a N-MLV<sub>L117H</sub> chimera [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>]. However, the role of v2 in species-specific lentiviral restriction has not yet been extensively tested.</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Codons under positive selection in <italic>TRIM5</italic>&#x003b1; and <italic>APOBEC3G</italic></bold>. Y-axis: Probabilities of positively selected codons (see text). X-axis: amino acid numbering and functional domains. <italic>TRIM19 </italic>is shown for comparison.</p></caption><graphic xlink:href="1742-4690-3-11-2"/></fig><p>The analysis also predicts a large number (24 of 384, 6%) of positively selected sites in the <italic>APOBEC3G </italic>(Figure <xref ref-type="fig" rid="F2">2B</xref>) sequence. This result is consistent with previous reports by Sawyer et al. [<xref ref-type="bibr" rid="B5">5</xref>]. However, the inclusion of several new species from an additional hominoid lineage, Hylobatidae (gibbons and siamangs), points to the existence of a cluster of residues under positive selection between amino acids 62 and 103, the region that defines the Vif-interaction domain [<xref ref-type="bibr" rid="B21">21</xref>]. The protein Vif, which counteracts the activity of APOBEC3G, is encoded by nearly all lentiviruses [<xref ref-type="bibr" rid="B22">22</xref>]. Within the Vif-interaction domain of APOBEC3G, 10 residues can be pinpointed to have evolved under strong positive selection. Interestingly, the APOBEC3G amino acid position 128, which controls the ability of the HIV-1 Vif protein to bind and inactivate this host defense factor [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>], is correctly identified as being positively selected (<italic>P </italic>&#x0003e; 0.987).</p><p>The parallel assessment of multiple genes in the same set of primates allows for several considerations and conclusions. First, by including additional primate lineages, we modify and complement previously observed patterns for two antiviral defense genes/proteins. For TRIM5&#x003b1;, our analysis confirms previous results by Sawyer et al [<xref ref-type="bibr" rid="B3">3</xref>], but underscores the potential interest of the second variable region of the SPRY domain that may be of functional relevance and merits further experimental analysis. With respect to APOBEC3G, our analysis extends previous reports that showed protein-wide distribution of positively selected residues. It suggests that this protein potentially carries a functionally relevant cluster of selected residues that coincides with the region of HIV-1-Vif interaction [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>]. Positive selected sites by Bayes Empirical Bayes Inference with probabilities P &#x0003e; 0.95 for the two proteins are listed in <xref ref-type="supplementary-material" rid="S3">Additional file 3</xref>.</p><p>Second, the failure to identify signatures of positive selection in the <italic>TRIM19 </italic>(<italic>PML</italic>) gene suggests that its encoded protein does not have antiviral activity, or that the protein acts as an intermediary, lacking a physical protein-protein interaction with the pathogen. TRIM19 (PML) has been implicated in many functions, for example, in apoptosis and cell proliferation [<xref ref-type="bibr" rid="B9">9</xref>]. In addition, TRIM19 (PML) expression may act as an effector of the antiviral state induced by type I interferons [<xref ref-type="bibr" rid="B9">9</xref>]. Overexpression of TRIM19 (PML) is reported to confer resistance to infection by vesicular stomatitis virus and influenza A virus. Rabies, Lassa virus and lymphocytic choriomeningitis virus replicate to higher levels in PML-negative cells, whereas overexpression of the protein has no significant effect. Various roles have been proposed for TRIM19 (PML) in retroviral replication [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B25">25</xref>], although these findings remain controversial [<xref ref-type="bibr" rid="B26">26</xref>]. Many other viruses, including herpes simplex type 1 disturb the nuclear bodies that contain, among other proteins, TRIM19 (PML). However, it is unclear whether these effects are a consequence of the viral infection or a sign of its participation in antiviral defense. Thus, the effect of TRIM19 (PML) might be indirect. Failure to identify a signature of positive selection militates against a direct role of this protein in antiviral defense, because it would be expected that a prolonged contact with multiple pathogens over long evolutionary time periods would have resulted in signatures of positive selection indicative of a genetic conflict.</p><p>Finally, the absence of a signature of positive Darwinian selection in Cyclophilin A provides a complement to the understanding of the role of this protein in retroviral pathogenesis. Cyclophilin A interacts directly with the HIV-1 capsid, an interaction that may protect HIV-1 from antiviral restriction activity [<xref ref-type="bibr" rid="B27">27</xref>]. Although required by members of the HIV-1M/SIV<sub>CPZ </sub>lineage for replication, it is not needed by other primate immunodeficiency viruses [<xref ref-type="bibr" rid="B11">11</xref>]. Owl monkeys exhibit post-entry restriction of HIV-1 mediated by a TRIM5-Cyclophilin A fusion protein generated by retroposition [<xref ref-type="bibr" rid="B28">28</xref>]. Evolutionary analysis of <italic>PPIA </italic>indicates that Cyclophilin A has been preserved by strong purifying selection, leaving its protein sequence virtually unchanged. This is consistent with the interaction of Cyclophilin A and the viral capsid being limited to the HIV-1M/SIVcpz lineage.</p><p>Together, the results presented here further support that an evolutionary genomics approach may be very useful for systematically assessing functional roles of primate host proteins potentially relevant in viral pathogenesis [<xref ref-type="bibr" rid="B29">29</xref>]. Candidates for this approach may include other members of the TRIM or APOBEC families [<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref>] as well as proteins involved in pathogen recognition and life cycle. Signatures of positive selection, but also the absence of signs of a genetic conflict, constitute relevant information for understanding the nature of virus-host protein interactions.</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>MO carried out the molecular genetic studies, performed sequence and phylogenetic analysis and contributed to drafting of the manuscript. GB and RM carried out molecular genetic studies. HK conceived the study, performed the evolutionary genomic analyses and drafted the manuscript. AT conceived the study, supervised the molecular genetic analysis, assured funding, and drafted the manuscript.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p>GenBank accession numbers.</p></caption><media xlink:href="1742-4690-3-11-S1.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S2"><caption><title>Additional file 2</title><p>Primers for amplification and sequence analysis.</p></caption><media xlink:href="1742-4690-3-11-S2.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S3"><caption><title>Additional file 3</title><p>Positive selected sites by Bayes Empirical Bayes Inference with probabilities P &#x0003e; 0.95.</p></caption><media xlink:href="1742-4690-3-11-S3.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>Supported by Swiss National Science Foundation grant no. 310000-110012/1 (to A.T.) and 3100A0-104181 (to H.K.), research awards of the Clo&#x000eb;tta and Leenaards Foundations (to A.T.), and a grant for interdisciplinary research from the Faculty of Biology and Medicine of the University of Lausanne (to A.T. and H.K.).</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name></person-group><article-title>The power of phylogenetic comparison in revealing protein function</article-title><source>Proc Natl Acad Sci U S A</source><year>2005</year><volume>102</volume><fpage>3179</fpage><lpage>3180</lpage><pub-id pub-id-type="pmid">15728394</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0500371102</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stremlau</surname><given-names>M</given-names></name><name><surname>Owens</surname><given-names>CM</given-names></name><name><surname>Perron</surname><given-names>MJ</given-names></name><name><surname>Kiessling</surname><given-names>M</given-names></name><name><surname>Autissier</surname><given-names>P</given-names></name><name><surname>Sodroski</surname><given-names>J</given-names></name></person-group><article-title>The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys</article-title><source>Nature</source><year>2004</year><volume>427</volume><fpage>848</fpage><lpage>853</lpage><pub-id pub-id-type="pmid">14985764</pub-id><pub-id pub-id-type="doi">10.1038/nature02343</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sawyer</surname><given-names>SL</given-names></name><name><surname>Wu</surname><given-names>LI</given-names></name><name><surname>Emerman</surname><given-names>M</given-names></name><name><surname>Malik</surname><given-names>HS</given-names></name></person-group><article-title>Positive selection of primate TRIM5{alpha} identifies a critical species-specific retroviral restriction domain</article-title><source>Proc Natl Acad Sci U S A</source><year>2005</year><volume>102</volume><fpage>2832</fpage><lpage>2837</lpage><pub-id pub-id-type="pmid">15689398</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0409853102</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sheehy</surname><given-names>AM</given-names></name><name><surname>Gaddis</surname><given-names>NC</given-names></name><name><surname>Choi</surname><given-names>JD</given-names></name><name><surname>Malim</surname><given-names>MH</given-names></name></person-group><article-title>Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein</article-title><source>Nature</source><year>2002</year><volume>418</volume><fpage>646</fpage><lpage>650</lpage><pub-id pub-id-type="pmid">12167863</pub-id><pub-id pub-id-type="doi">10.1038/nature00939</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sawyer</surname><given-names>SL</given-names></name><name><surname>Emerman</surname><given-names>M</given-names></name><name><surname>Malik</surname><given-names>HS</given-names></name></person-group><article-title>Ancient Adaptive Evolution of the Primate Antiviral DNA-Editing Enzyme APOBEC3G</article-title><source>PLoS Biol</source><year>2004</year><volume>2</volume><fpage>E275</fpage><pub-id pub-id-type="pmid">15269786</pub-id><pub-id pub-id-type="doi">10.1371/journal.pbio.0020275</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Webb</surname><given-names>DM</given-names></name></person-group><article-title>Rapid evolution of primate antiviral enzyme APOBEC3G</article-title><source>Hum Mol Genet</source><year>2004</year><volume>13</volume><fpage>1785</fpage><lpage>1791</lpage><pub-id pub-id-type="pmid">15198990</pub-id><pub-id pub-id-type="doi">10.1093/hmg/ddh183</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goodman</surname><given-names>M</given-names></name></person-group><article-title>The genomic record of Humankind's evolutionary roots</article-title><source>Am J Hum Genet</source><year>1999</year><volume>64</volume><fpage>31</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">9915940</pub-id><pub-id pub-id-type="doi">10.1086/302218</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Turelli</surname><given-names>P</given-names></name><name><surname>Doucas</surname><given-names>V</given-names></name><name><surname>Craig</surname><given-names>E</given-names></name><name><surname>Mangeat</surname><given-names>B</given-names></name><name><surname>Klages</surname><given-names>N</given-names></name><name><surname>Evans</surname><given-names>R</given-names></name><name><surname>Kalpana</surname><given-names>G</given-names></name><name><surname>Trono</surname><given-names>D</given-names></name></person-group><article-title>Cytoplasmic recruitment of INI1 and PML on incoming HIV preintegration complexes: interference with early steps of viral replication</article-title><source>Mol Cell</source><year>2001</year><volume>7</volume><fpage>1245</fpage><lpage>1254</lpage><pub-id pub-id-type="pmid">11430827</pub-id><pub-id pub-id-type="doi">10.1016/S1097-2765(01)00255-6</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nisole</surname><given-names>S</given-names></name><name><surname>Stoye</surname><given-names>JP</given-names></name><name><surname>Saib</surname><given-names>A</given-names></name></person-group><article-title>TRIM family proteins: retroviral restriction and antiviral defence</article-title><source>Nat Rev Microbiol</source><year>2005</year><volume>3</volume><fpage>799</fpage><lpage>808</lpage><pub-id pub-id-type="pmid">16175175</pub-id><pub-id pub-id-type="doi">10.1038/nrmicro1248</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Franke</surname><given-names>EK</given-names></name><name><surname>Luban</surname><given-names>J</given-names></name></person-group><article-title>Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction</article-title><source>Virology</source><year>1996</year><volume>222</volume><fpage>279</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">8806510</pub-id><pub-id pub-id-type="doi">10.1006/viro.1996.0421</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Braaten</surname><given-names>D</given-names></name><name><surname>Franke</surname><given-names>EK</given-names></name><name><surname>Luban</surname><given-names>J</given-names></name></person-group><article-title>Cyclophilin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus SIV(CPZ)GAB but not group O HIV-1 or other primate immunodeficiency viruses</article-title><source>J Virol</source><year>1996</year><volume>70</volume><fpage>4220</fpage><lpage>4227</lpage><pub-id pub-id-type="pmid">8676442</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name></person-group><article-title>PAML: a program package for phylogenetic analysis by maximum likelihood</article-title><source>Comput Appl Biosci</source><year>1997</year><volume>13</volume><fpage>555</fpage><lpage>556</lpage><pub-id pub-id-type="pmid">9367129</pub-id></citation></ref><ref id="B13"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Li</surname><given-names>WH</given-names></name></person-group><source>Molecular evolution</source><year>1997</year><publisher-name>Sunderland MA, Sinauer Associates</publisher-name></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Bielawski</surname><given-names>JP</given-names></name></person-group><article-title>Statistical methods for detecting molecular adaptation</article-title><source>Trends Ecol Evo</source><year>2000</year><volume>15</volume><fpage>496</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1016/S0169-5347(00)01994-7</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Nielsen</surname><given-names>R</given-names></name><name><surname>Goldman</surname><given-names>N</given-names></name><name><surname>Pedersen</surname><given-names>AM</given-names></name></person-group><article-title>Codon-substitution models for heterogeneous selection pressure at amino acid sites</article-title><source>Genetics</source><year>2000</year><volume>155</volume><fpage>431</fpage><lpage>449</lpage><pub-id pub-id-type="pmid">10790415</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Wong</surname><given-names>WS</given-names></name><name><surname>Nielsen</surname><given-names>R</given-names></name></person-group><article-title>Bayes empirical bayes inference of amino acid sites under positive selection</article-title><source>Mol Biol Evol</source><year>2005</year><volume>22</volume><fpage>1107</fpage><lpage>1118</lpage><pub-id pub-id-type="pmid">15689528</pub-id><pub-id pub-id-type="doi">10.1093/molbev/msi097</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name></person-group><article-title>Likelihood ratio tests for detecting positive selection and application to primate lysozyme evolution</article-title><source>Mol Biol Evol</source><year>1998</year><volume>15</volume><fpage>568</fpage><lpage>573</lpage><pub-id pub-id-type="pmid">9580986</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>B</given-names></name><name><surname>Gold</surname><given-names>B</given-names></name><name><surname>O'Huigin</surname><given-names>C</given-names></name><name><surname>Javanbakht</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Stremlau</surname><given-names>M</given-names></name><name><surname>Winkler</surname><given-names>C</given-names></name><name><surname>Dean</surname><given-names>M</given-names></name><name><surname>Sodroski</surname><given-names>J</given-names></name></person-group><article-title>The B30.2(SPRY) domain of the retroviral restriction factor TRIM5alpha exhibits lineage-specific length and sequence variation in primates</article-title><source>J Virol</source><year>2005</year><volume>79</volume><fpage>6111</fpage><lpage>6121</lpage><pub-id pub-id-type="pmid">15857996</pub-id><pub-id pub-id-type="doi">10.1128/JVI.79.10.6111-6121.2005</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stremlau</surname><given-names>M</given-names></name><name><surname>Perron</surname><given-names>M</given-names></name><name><surname>Welikala</surname><given-names>S</given-names></name><name><surname>Sodroski</surname><given-names>J</given-names></name></person-group><article-title>Species-Specific Variation in the B30.2(SPRY) Domain of TRIM5{alpha} Determines the Potency of Human Immunodeficiency Virus Restriction</article-title><source>J Virol</source><year>2005</year><volume>79</volume><fpage>3139</fpage><lpage>3145</lpage><pub-id pub-id-type="pmid">15709033</pub-id><pub-id pub-id-type="doi">10.1128/JVI.79.5.3139-3145.2005</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yap</surname><given-names>MW</given-names></name><name><surname>Nisole</surname><given-names>S</given-names></name><name><surname>Stoye</surname><given-names>JP</given-names></name></person-group><article-title>A Single Amino Acid Change in the SPRY Domain of Human Trim5alpha Leads to HIV-1 Restriction</article-title><source>Curr Biol</source><year>2005</year><volume>15</volume><fpage>73</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">15649369</pub-id><pub-id pub-id-type="doi">10.1016/j.cub.2004.12.042</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Conticello</surname><given-names>SG</given-names></name><name><surname>Harris</surname><given-names>RS</given-names></name><name><surname>Neuberger</surname><given-names>MS</given-names></name></person-group><article-title>The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G</article-title><source>Curr Biol</source><year>2003</year><volume>13</volume><fpage>2009</fpage><lpage>2013</lpage><pub-id pub-id-type="pmid">14614829</pub-id><pub-id pub-id-type="doi">10.1016/j.cub.2003.10.034</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gaddis</surname><given-names>NC</given-names></name><name><surname>Sheehy</surname><given-names>AM</given-names></name><name><surname>Ahmad</surname><given-names>KM</given-names></name><name><surname>Swanson</surname><given-names>CM</given-names></name><name><surname>Bishop</surname><given-names>KN</given-names></name><name><surname>Beer</surname><given-names>BE</given-names></name><name><surname>Marx</surname><given-names>PA</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Bibollet-Ruche</surname><given-names>F</given-names></name><name><surname>Hahn</surname><given-names>BH</given-names></name><name><surname>Malim</surname><given-names>MH</given-names></name></person-group><article-title>Further investigation of simian immunodeficiency virus Vif function in human cells</article-title><source>J Virol</source><year>2004</year><volume>78</volume><fpage>12041</fpage><lpage>12046</lpage><pub-id pub-id-type="pmid">15479843</pub-id><pub-id pub-id-type="doi">10.1128/JVI.78.21.12041-12046.2004</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schrofelbauer</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Landau</surname><given-names>NR</given-names></name></person-group><article-title>A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif)</article-title><source>Proc Natl Acad Sci U S A</source><year>2004</year><volume>101</volume><fpage>3927</fpage><lpage>3932</lpage><pub-id pub-id-type="pmid">14978281</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0307132101</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mangeat</surname><given-names>B</given-names></name><name><surname>Turelli</surname><given-names>P</given-names></name><name><surname>Liao</surname><given-names>S</given-names></name><name><surname>Trono</surname><given-names>D</given-names></name></person-group><article-title>A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>14481</fpage><lpage>14483</lpage><pub-id pub-id-type="pmid">14966139</pub-id><pub-id pub-id-type="doi">10.1074/jbc.C400060200</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Regad</surname><given-names>T</given-names></name><name><surname>Saib</surname><given-names>A</given-names></name><name><surname>Lallemand-Breitenbach</surname><given-names>V</given-names></name><name><surname>Pandolfi</surname><given-names>PP</given-names></name><name><surname>de</surname><given-names>TH</given-names></name><name><surname>Chelbi-Alix</surname><given-names>MK</given-names></name></person-group><article-title>PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator</article-title><source>EMBO J</source><year>2001</year><volume>20</volume><fpage>3495</fpage><lpage>3505</lpage><pub-id pub-id-type="pmid">11432836</pub-id><pub-id pub-id-type="doi">10.1093/emboj/20.13.3495</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berthoux</surname><given-names>L</given-names></name><name><surname>Towers</surname><given-names>GJ</given-names></name><name><surname>Gurer</surname><given-names>C</given-names></name><name><surname>Salomoni</surname><given-names>P</given-names></name><name><surname>Pandolfi</surname><given-names>PP</given-names></name><name><surname>Luban</surname><given-names>J</given-names></name></person-group><article-title>As(2)O(3) enhances retroviral reverse transcription and counteracts Ref1 antiviral activity</article-title><source>J Virol</source><year>2003</year><volume>77</volume><fpage>3167</fpage><lpage>3180</lpage><pub-id pub-id-type="pmid">12584341</pub-id><pub-id pub-id-type="doi">10.1128/JVI.77.5.3167-3180.2003</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Franke</surname><given-names>EK</given-names></name><name><surname>Yuan</surname><given-names>HE</given-names></name><name><surname>Luban</surname><given-names>J</given-names></name></person-group><article-title>Specific incorporation of cyclophilin A into HIV-1 virions</article-title><source>Nature</source><year>1994</year><volume>372</volume><fpage>359</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">7969494</pub-id><pub-id pub-id-type="doi">10.1038/372359a0</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sayah</surname><given-names>DM</given-names></name><name><surname>Sokolskaja</surname><given-names>E</given-names></name><name><surname>Berthoux</surname><given-names>L</given-names></name><name><surname>Luban</surname><given-names>J</given-names></name></person-group><article-title>Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1</article-title><source>Nature</source><year>2004</year><volume>430</volume><fpage>569</fpage><lpage>573</lpage><pub-id pub-id-type="pmid">15243629</pub-id><pub-id pub-id-type="doi">10.1038/nature02777</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Telenti</surname><given-names>A</given-names></name></person-group><article-title>Adaptation, co-evolution, and human susceptibility to HIV-1 infection</article-title><source>Infect Genet Evol</source><year>2005</year><volume>5</volume><fpage>327</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">16168938</pub-id><pub-id pub-id-type="doi">10.1016/j.meegid.2004.11.001</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reymond</surname><given-names>A</given-names></name><name><surname>Meroni</surname><given-names>G</given-names></name><name><surname>Fantozzi</surname><given-names>A</given-names></name><name><surname>Merla</surname><given-names>G</given-names></name><name><surname>Cairo</surname><given-names>S</given-names></name><name><surname>Luzi</surname><given-names>L</given-names></name><name><surname>Riganelli</surname><given-names>D</given-names></name><name><surname>Zanaria</surname><given-names>E</given-names></name><name><surname>Messali</surname><given-names>S</given-names></name><name><surname>Cainarca</surname><given-names>S</given-names></name><name><surname>Guffanti</surname><given-names>A</given-names></name><name><surname>Minucci</surname><given-names>S</given-names></name><name><surname>Pelicci</surname><given-names>PG</given-names></name><name><surname>Ballabio</surname><given-names>A</given-names></name></person-group><article-title>The tripartite motif family identifies cell compartments</article-title><source>EMBO J</source><year>2001</year><volume>20</volume><fpage>2140</fpage><lpage>2151</lpage><pub-id pub-id-type="pmid">11331580</pub-id><pub-id pub-id-type="doi">10.1093/emboj/20.9.2140</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bogerd</surname><given-names>HP</given-names></name><name><surname>Wiegand</surname><given-names>HL</given-names></name><name><surname>Doehle</surname><given-names>BP</given-names></name><name><surname>Lueders</surname><given-names>KK</given-names></name><name><surname>Cullen</surname><given-names>BR</given-names></name></person-group><article-title>APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells</article-title><source>Nucleic Acids Res</source><year>2006</year><volume>34</volume><fpage>89</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">16407327</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkj416</pub-id></citation></ref></ref-list></back></article> 